Navigation Links
FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
Date:10/1/2009

WAYNE, N.J., Oct. 1 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for Mirena® (levonorgestrel-releasing intrauterine system) for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena provides an effective, non-surgical option for the treatment of heavy menstrual bleeding and is the first and only contraceptive approved in the U.S. for this indication.

Heavy menstrual bleeding is a problem that affects between nine and 14 percent of otherwise healthy women(1) and is a common reason a woman sees her doctor. Heavy menstrual bleeding is defined as menstrual cycles with 5 tablespoons or more of blood loss (> 80 mL). Signs of heavy menstrual bleeding include:

  • the need to use double sanitary protection to control the heavy flow
  • menstrual flow that soaks through one or more sanitary pads or tampons every hour
  • the need to change sanitary protection during the night(2)

"Many women with heavy periods often suffer privately with their symptoms. And because approved effective non-surgical treatment options are limited, women who do seek treatment for heavy periods often face the choice of having surgical procedures, such as hysterectomies" said Dr. Andrew Kaunitz, M.D., FACOG, Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. "In a clinical trial, nearly nine out of 10 women were treated successfully for heavy menstrual bleeding with Mirena -- meaning it reduced monthly blood loss by more than 50 percent from baseline and to below 80 milliliters. This makes it an effective, nonsurgical first-line option."

"Mirena has a proven track-record as an effective contraceptive that lasts for up to five years. We are pleased to
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
2. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
3. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
4. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
5. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
6. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
7. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
8. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
9. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
10. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
11. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... UPPSALA, Sweden, and WILMINGTON, Mass., March 28 ... accurate assessment of translesion,pressure gradients when compared to ... published in the Journal of,Interventional Cardiology (2008; Vol. ... that although CPG measurements derived from both a,catheter ...
... of TRU-016, Trubion,s Proprietary ... Product Candidate, SBI-087 for RA Expands Trubion,s Family of Customized, ... Product ... that it has initiated a Phase 1/2,clinical trial of TRU-016, the company,s lead proprietary ...
Other Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 2Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 3Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 4Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update 5
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... Association to raise funds,through in-store ,pin-up, campaign, ALEXANDRIA, ... announced that Kmart has reinforced its,commitment to ADA and ... National Strategic Partner (NSP). As a National Strategic,Partner, Kmart ... mission to,prevent and cure diabetes, and to improve the ...
... to have active are:,Anthony Leiserowitz ... New Haven, Conn. A growing number of Americans ... action, and 40% say that a presidential candidates position on ... a national survey conducted by Yale University, Gallup and the ...
... 1, 2007 - When a child is farsighted or ... bilateral amblyopia may develop. In contrast to single-eye amblyopia ... image to the brain, bilateral amblyopia affects both eyes ... the October issue of the American Journal of Ophthalmology, ...
... 1, 2007 Newer ultrasound and magnetic resonance ... diagnosing fibrosis (scarring) and cirrhosis of the liver, ... of the journal Clinical Gastroenterology and Hepatology. , ... techniques may reduce the need for biopsiesprocedures done ...
... chance of trouble down the road, study says , , MONDAY, Oct. ... of TV, turn it off now and save yourself a lot ... that suggests that the negative effects of lots of early TV ... age of 6. , The study doesn,t confirm that television is ...
... assess the stability of three aspects of sleep behavior ... of mortality in short sleep, long sleep and frequent ... the October 1 issue of the journal SLEEP. , ... the Finnish Institute of Occupational Health in Helsinki, Finland, ...
Other Medicine News:Health News:Kmart Steps Out to Fight Diabetes 2Health News:Kmart Steps Out to Fight Diabetes 3Health News:Americans consider global warming an urgent threat, according to poll 2Health News:Early treatment of children with bilateral amblyopia essential, according to multisite study 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 3Health News:Kids' TV Viewing Tied to Behavioral Problems 2Health News:Kids' TV Viewing Tied to Behavioral Problems 3Health News:Both short and long sleep is associated with increased mortality 2
... The ReSeeVit 5Z slit lamp is ... video imaging. This video-ready slit lamp ... source. It is another addition to ... that offers the best products on ...
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
Remote Control Vision Tester Can Administer Basic,Distance Vision Tests in Less Than 2 Minutes....
Medicine Products: